GCAN signs licensing/research deal with Shaare Zedek for cannabinoid therapy targeting neuropsychiatric disorders

Greater Cannabis Company, Inc.

Licensing covers novel cannabinoid therapeutic for autism, schizophrenia, Parkinson's, Alzheimer's, and other neuropsychiatric disorders.
Joint R&D agreement with Shaare Zedek Scientific, technology transfer arm of Jerusalem's Shaare Zedek Medical Center.
Dr. Adi Aran, SZMC pediatric neurology director and cannabis research pioneer, will lead continued clinical program.
Director David Tavor resigned effective August 19, 2021.
No financial terms of the agreements were disclosed.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Tavor

director

GCAN · Greater Cannabis Company, Inc.

Effective: 2021-08-19
Filed: August 19, 2021, 7:59 PM ET

Effective August 19, 2021, David Tavor resigned as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Tavor resigned as director at Greater Cannabis Company, Inc..

Action: resigned
Role: director

Exact text from the filing

Effective August 19, 2021, David Tavor resigned as a director of the Company.

View on SEC.gov

Greater Cannabis Company, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-020666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.